Read Full Article
Irish pharmaceutical company Actavis will buy Allergan, the maker of Botox, for $219 per share in cash and stock, the company said in a press release...
This acquisition creates the fastest growing and most dynamic growth pharmaceutical company in global healthcare, making us one of the world's top 10 pharmaceutical companies.
With this combination, we plan to transform the growth profile of our pharmaceutical business and have the ability to generate organic revenue growth at a compound annual growth rate of at least 10 percent for the foreseeable future.
Today's transaction provides Allergan stockholders with substantial and immediate value, as well as the opportunity to participate in the significant upside potential of the combined company, We are combining with a partner that is ideally suited to realize the full potential inherent in our franchise.